Continued Testing of M-BAND is Part of the JUPITR program to Provide Advanced Biological Detection Capabilities for Stronger Bio-Surveillance on the Korean Peninsula to Protect U.S. Military and Allies
DELRAY BEACH, Fla., Aug. 20, 2014 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (PSID), a developer of biological detection and diagnostics solutions, today announced that its M-BAND (Microfluidic-based Bioagent Autonomous Networked Detector) system has been sent to the Korean peninsula for continued testing as part of The Joint United States Forces Korea Portal and Integrated Threat Recognition (JUPITR), a program led by the Joint Program Executive Office for Chemical and Biological Defense and supported by the U.S. Army Edgewood Chemical Biological Center, to provide unique biological detection capabilities for advanced bio-surveillance on the Korean peninsula.
PositiveID previously announced an agreement with a large government contractor to support the U.S. Department of Defense (“DoD”) JUPITR Program. As part of this program, M-BAND is being tested and evaluated to baseline performance, reliability, maintainability, ease of use, and cost of operation to provide the “best of breed” and most affordable options for the U.S. Army and U.S. Air Force.
“We are very proud to work with our partners and the U.S. government to evaluate M-BAND, which we believe offers more rapid and accurate biosurveillance in order to provide enhanced protection for U.S. forces in Korea,” said William J. Caragol, Chairman and CEO of PositiveID.
Supporting organizations for JUPITR include the Department of Homeland Security, Office of the Assistant Secretary of Defense for Health Affairs, Health Affairs and Defense Threat Reduction Agency.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID’s future expectations, including the likelihood that M-BAND offers more rapid and accurate biosurveillance in order to provide enhanced protection for U.S. forces in Korea, and all statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 11, 2014, and 10-Qs filed on August 14, 2014, May 20, 2014, and November 19, 2013, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.